Prenetics Global (NASDAQ:PRE) Shares Down 2.6% – Should You Sell?

Prenetics Global Limited (NASDAQ:PRE)’s share price fell 2.6% during trading on Monday . The company traded as low as $5.10 and last traded at $5.25. 8,525 shares were traded during mid-day trading, a decline of 50% from the average session volume of 17,120 shares. The stock had previously closed at $5.39.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $9.00 price objective on shares of Prenetics Global in a research note on Thursday, January 16th.

Prenetics Global Price Performance

The business has a 50 day moving average price of $4.37 and a 200 day moving average price of $4.91. The firm has a market capitalization of $64.08 million, a P/E ratio of -1.32 and a beta of -0.26.

Hedge Funds Weigh In On Prenetics Global

An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC acquired a new stake in shares of Prenetics Global Limited (NASDAQ:PRE) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned approximately 0.10% of Prenetics Global at the end of the most recent quarter. Institutional investors own 25.01% of the company’s stock.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.